Our team

Philippe Monteyne holds an M.D. degree trained as a Neurologist and a Ph.D. in Viral Immunology, both at the UCL (Univ. Cathol. de Louvain), followed by a post-doctoral fellowship at Pasteur Institute, Paris. During the last 20 years, he held senior positions in top pharma companies such as SmithKline Beecham, GSK Biologicals (as Head of Global Vaccine Development) and GSK Rare Diseases (Head of Development and Chief Medical Officer) and SANOFI (Vice President R&D France). He is also currently member of different Strategic Advisory Committees and Board of Directors, in Belgium, France and Spain. He is also visiting Professor of Neurology at the UCL.

Caroline Goddeeris holds a PhD in Pharmaceutical Sciences followed by an MBA and master in corporate finance, both from Vlerick Business School. She started her career at UCB taking on various roles in strategy (portfolio management, business development, new product planning) and operations (marketing and sales). Prior to joining Fund+, Caroline was a principal at Gimv with board responsibilities at Complix and Multiplicom (sold to Agilent). Caroline currently serves on the board of Confo Therapeutics, TargED Biopharmaceuticals and Astrivax.

Bart joined Fund+ in 2023.  Prior to joining Fund+, Bart worked at Ackermans & van Haaren as Group Controller and Investment Manager and as CFO/Risk Officer at Fortino Capital Partners. For most of his career, he worked at Ernst&Young where he progressed as Head of the Technical Desk. He was part of the EY global expert group in London. Bart holds a master’s degree in Commercial Sciences and in Business Information Systems from the University of Brussels.

Halina Novak holds a Ph.D. in Biological Science from the University of Exeter, UK. She started her career with an industry sponsored postdoctoral fellowship, where she worked on industrial applications of enzymes for Unilever, which resulted in a number of granted patents. Halina went on to work at VIB, at the intersection between industry and academia where she held several positions in Technology and Innovation. Notably, she headed the Tech Watch Program and Technology Innovation Lab, where unique strategies were developed to identify, evaluate and implement breakthrough life science technologies. During her 8 years at VIB, she managed a portfolio of projects with companies developing breakthrough technologies, which resulted in many successful investments in cutting edge tools that have since revolutionised the Life Sciences. Halina currently represents Fund+ as a Board member of Indigo, and as a Board Observer of TargED Biopharmaceuticals and EyeD Pharma.

Lawrence holds a Ph.D. in Biomedical Sciences from the VIB-KU Leuven Centre of Brain & Disease Research. There, he focused on the pathophysiology underlying peripheral neuropathies which contributed to the successful creation of Augustine Therapeutics, a spin-off intended to give clinical answers to devastating neuromuscular and neurodegenerative disorders. After his academic passage, Lawrence made the transition to start-up biotech and worked for more than 3 years as a Senior Scientist at CoBioRes NV, converging the preclinical development of targeted anti-cancer therapies. His tremendous desire to work on the frontline of upcoming technologies and innovations directed him towards Fund+, where he joined the team as Scientific Investment Analyst in the fall of 2021.

Diane holds a bachelor degree in informatics. She worked as administrative assistant and bookkeeper for several companies such as ADB (Siemens), VIB and Life Sciences Research Partners (still currently).